BiotechTube
Cell2Cure

Cell2Cure

Copenhagen, Denmark· Est.
celltocure.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $21M

Overview

Cell2Cure is a privately held, clinical-stage biotech based in Copenhagen, Denmark, founded in 2015 as a spinout from Rigshospitalet. The company has developed a proprietary GMP manufacturing process for its allogeneic adipose-derived MSC product, which has demonstrated a strong safety profile in over 300 patients across various indications. With a pipeline focused on inflammatory and autoimmune conditions, Cell2Cure operates through in-house development and strategic collaborations, positioning itself in the growing regenerative medicine market.

AutoimmuneInflammatoryCardiovascularNeurologicalWound HealingOphthalmology

Technology Platform

Proprietary GMP manufacturing process for off-the-shelf, allogeneic adipose-derived mesenchymal stromal/stem cells (MSCs). The cells exert therapeutic effects through immunomodulation, anti-inflammatory signaling, and promotion of tissue repair.

Funding History

2
Total raised:$21M
Series A$18M
Seed$3M

Opportunities

The broad immunomodulatory mechanism of its MSC platform allows efficient expansion into large markets with high unmet need, such as autoimmune and inflammatory diseases.
Its established GMP manufacturing and strong safety data position it as an attractive development and manufacturing partner for other organizations in the cell therapy space.

Risk Factors

The company faces significant clinical risk as its pipeline is in early stages, and efficacy in late-stage trials is unproven.
As a pre-revenue company, it remains dependent on continued funding from its majority owner and grants, introducing financial runway risk.

Competitive Landscape

Cell2Cure operates in the competitive allogeneic MSC therapy space, competing with other biotechs and large pharma partners developing similar off-the-shelf cell products. Differentiation will depend on demonstrating superior efficacy, a unique product profile, or advantages in manufacturing scalability and cost.

More companies in Cell & Gene Therapy →More companies in Denmark →